{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:01:21Z","timestamp":1780959681953,"version":"3.54.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["512648189"],"award-info":[{"award-number":["512648189"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Open Access Publication Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Post-traumatic osteomyelitis attributed to metallo-\u03b2-lactamase (MBL)-producing Gram-negative bacteria presents a challenging clinical scenario. Cefiderocol emerges as a viable treatment option within the limited therapeutic options available.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patient\/case description<\/jats:title>\n                  <jats:p>In this brief report, we present a case of a Ukrainian patient with osteomyelitis caused by multi-drug resistant Pseudomonas aeruginosa, which was successfully treated with cefiderocol, facilitated in part by outpatient parenteral antibiotic therapy (OPAT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results and discussion<\/jats:title>\n                  <jats:p>Administration of Cefiderocol via OPAT can present a safe and effective option for treatment of post-traumatic osteomyelitis with multi-drug resistant Pseudomonas aeruginosa. A possible effect on iron homeostasis of extended treatment duration with cefiderocol may be taken into consideration.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlae015","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T16:06:40Z","timestamp":1707322000000},"source":"Crossref","is-referenced-by-count":8,"title":["Successful outpatient parenteral antibiotic therapy with cefiderocol for osteomyelitis caused by multi-drug resistant Gram-negative bacteria: a case report"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5382-0083","authenticated-orcid":false,"given":"Paul","family":"Schellong","sequence":"first","affiliation":[{"name":"Institute for Infectious Diseases and Infection Control, Jena University Hospital\u2014Friedrich Schiller University Jena , Am Klinikum 1 , 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janett","family":"Wennek-Klose","sequence":"additional","affiliation":[{"name":"Hospital Care, Medipolis Intensive Care & Service GmbH Pharmaceutical OPAT Service Provider , Jena , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Spiegel","sequence":"additional","affiliation":[{"name":"Department of Trauma, Hand and Reconstructive Surgery, Jena University Hospital\u2014Friedrich Schiller University Jena , Jena , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"R\u00f6del","sequence":"additional","affiliation":[{"name":"Institute of Medical Microbiology, Jena University Hospital, Friedrich Schiller University , Jena , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-6131","authenticated-orcid":false,"given":"Stefan","family":"Hagel","sequence":"additional","affiliation":[{"name":"Institute for Infectious Diseases and Infection Control, Jena University Hospital\u2014Friedrich Schiller University Jena , Am Klinikum 1 , 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"2024022909294941600_dlae015-B1","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s15010-023-02061-4","article-title":"Multidrug-resistant isolates from Ukrainian patients in a German health facility: a genomic surveillance study focusing on antimicrobial resistance and bacterial relatedness","volume":"51","author":"Stein","year":"2023","journal-title":"Infection"},{"key":"2024022909294941600_dlae015-B2","doi-asserted-by":"crossref","first-page":"2200850","DOI":"10.2807\/1560-7917.ES.2023.28.1.2200850","article-title":"Molecular surveillance of multidrug-resistant Gram-negative bacteria in Ukrainian patients, Germany, March to June 2022","volume":"28","author":"Schultze","year":"2023","journal-title":"Euro Surveill"},{"key":"2024022909294941600_dlae015-B3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41579-022-00686-0","article-title":"Skeletal infections: microbial pathogenesis, immunity and clinical management","volume":"20","author":"Masters","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"2024022909294941600_dlae015-B4","doi-asserted-by":"crossref","first-page":"e01454-17","DOI":"10.1128\/AAC.01454-17","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria","volume":"62","author":"Ito","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024022909294941600_dlae015-B5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024022909294941600_dlae015-B6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024022909294941600_dlae015-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciy867","article-title":"2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024022909294941600_dlae015-B8","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3390\/microorganisms8081236","article-title":"Compassionate use of cefiderocol to treat a case of prosthetic joint infection due to extensively drug-resistant enterobacter hormaechei","volume":"8","author":"Sim\u00e9on","year":"2020","journal-title":"Microorganisms"},{"key":"2024022909294941600_dlae015-B9","doi-asserted-by":"crossref","first-page":"ofaa150","DOI":"10.1093\/ofid\/ofaa150","article-title":"Case report: successful rescue therapy of extensively drug-resistant Acinetobacter baumannii osteomyelitis with cefiderocol","volume":"7","author":"Dagher","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2024022909294941600_dlae015-B10","doi-asserted-by":"crossref","first-page":"e01872-19","DOI":"10.1128\/AAC.01872-19","article-title":"Long-term compassionate use of cefiderocol to treat chronic osteomyelitis caused by extensively drug-resistant Pseudomonas aeruginosa and extended-spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae in a pediatric patient","volume":"64","author":"Alamarat","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024022909294941600_dlae015-B11","doi-asserted-by":"crossref","first-page":"e00700-17","DOI":"10.1128\/AAC.00700-17","article-title":"Efficacy of cefiderocol against carbapenem-resistant Gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics","volume":"61","author":"Matsumoto","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024022909294941600_dlae015-B12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40261-023-01257-8","article-title":"Feasibility of continuous infusion of cefiderocol in conjunction with the establishment of therapeutic drug monitoring in patients with extensively drug-resistant Gram-negative bacteria","volume":"43","author":"Prinz","year":"2023","journal-title":"Clin Drug Investig"},{"key":"2024022909294941600_dlae015-B13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jgar.2021.10.014","article-title":"A descriptive case series of pharmacokinetic\/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and\/or ventilator-associated pneumonia treated with cefiderocol","volume":"27","author":"Gatti","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2024022909294941600_dlae015-B14","doi-asserted-by":"crossref","first-page":"e01009-23","DOI":"10.1128\/aac.01009-23","article-title":"The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy","volume":"68","author":"Teran","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2024022909294941600_dlae015-B15","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2024022909294941600_dlae015-B16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024022909294941600_dlae015-B17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10096-021-04399-9","article-title":"Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study","volume":"41","author":"Skaar","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/1\/dlae015\/56756014\/dlae015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/1\/dlae015\/56756014\/dlae015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T09:32:05Z","timestamp":1709199125000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlae015\/7602547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlae015","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,12,28]]},"article-number":"dlae015"}}